Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

levodopa

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.


Read more:

Researchers create Parkinson’s-resistant stem cells

Memory loss could be an indication of Parkinson’s

Go Back

Share this story

Comments


Related articles


he-big-life-fix-emma-lawton

Advances

“I can draw again” – how a smart watch helped a graphic designer overcome her Parkinson’s tremor

Vibrating watch helps graphic designer draw again

READ MORE
Kim Petrie with The Trews

Interviews

Kim Petrie: “How I raised $250,000 for Parkinson’s research”

Kim Petrie tells us how she raised $250,000 to fight Parkinson’s

READ MORE
Timo's travel tips

Perspectives

10 top tips for travelling with Parkinson’s

Finnish author and campaigner Timo Montonen shares his top tips

READ MORE